CA2354779A1 - Tricyclic farnesyl protein transferase inhibitors - Google Patents

Tricyclic farnesyl protein transferase inhibitors Download PDF

Info

Publication number
CA2354779A1
CA2354779A1 CA002354779A CA2354779A CA2354779A1 CA 2354779 A1 CA2354779 A1 CA 2354779A1 CA 002354779 A CA002354779 A CA 002354779A CA 2354779 A CA2354779 A CA 2354779A CA 2354779 A1 CA2354779 A1 CA 2354779A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
aryl
arylalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002354779A
Other languages
English (en)
French (fr)
Inventor
Arthur G. Taveras
Ronald J. Doll
Alan B. Cooper
Johan A. Ferreira
Timothy Guzi
Alan K. Mallams
Dinanath F. Rane
Viyyoor M. Girijavallabhan
Adriano Afonso
Cynthia J. Aki
Jianping Chao
Carmen Alvarez
Joseph M. Kelly
Tarik Lalwani
Jagdish A. Desai
James J.S. Wang
Jay Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2354779A1 publication Critical patent/CA2354779A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002354779A 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors Abandoned CA2354779A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
US09/216,398 1998-12-18
PCT/US1999/027939 WO2000037459A1 (en) 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors

Publications (1)

Publication Number Publication Date
CA2354779A1 true CA2354779A1 (en) 2000-06-29

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002354779A Abandoned CA2354779A1 (en) 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors

Country Status (20)

Country Link
EP (1) EP1140902A1 (https=)
JP (1) JP2002533336A (https=)
KR (1) KR20010081116A (https=)
CN (1) CN1326850C (https=)
AR (1) AR021718A1 (https=)
AU (1) AU776558B2 (https=)
BR (1) BR9916314A (https=)
CA (1) CA2354779A1 (https=)
CO (1) CO5160350A1 (https=)
CZ (1) CZ20011950A3 (https=)
HU (1) HUP0202152A2 (https=)
IL (1) IL143408A0 (https=)
NO (1) NO20012961L (https=)
NZ (1) NZ511878A (https=)
PE (1) PE20001342A1 (https=)
PL (1) PL348293A1 (https=)
SK (1) SK7592001A3 (https=)
TR (1) TR200101755T2 (https=)
WO (1) WO2000037459A1 (https=)
ZA (1) ZA200104233B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL348293A1 (en) 1998-12-18 2002-05-20 Schering Corp Tricyclic farnesyl protein transferase inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AU2002236813A1 (en) 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
MX2007007074A (es) 2004-12-13 2007-09-04 Schering Corp Inhibidores novedosos de proteina transferasa de farnesilo y su uso para tratar cancer.
CA2591123A1 (en) 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
JP6633539B2 (ja) 2014-03-19 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(5−置換−ピリジン−2−イル)−3−(1h−テトラゾール−1−イル)プロパン−2−オールおよびその調製工程
BR112016021257B1 (pt) * 2014-03-19 2021-03-02 Viamet Pharmaceuticals (NC), Inc. 2-(2,4- difluorofenil-1,1-diflúor-1-(5-substituído-piridin-2-il)-3- (1h-tetrazol-1-il)propan-2-óis e processos para preparação e uso dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5801175A (en) 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
HUP0003138A3 (en) * 1997-06-17 2002-11-28 Schering Corp Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
PL348293A1 (en) 1998-12-18 2002-05-20 Schering Corp Tricyclic farnesyl protein transferase inhibitors

Also Published As

Publication number Publication date
AU776558B2 (en) 2004-09-16
NO20012961L (no) 2001-08-16
TR200101755T2 (tr) 2001-09-21
EP1140902A1 (en) 2001-10-10
AR021718A1 (es) 2002-07-31
CN1334811A (zh) 2002-02-06
AU2030700A (en) 2000-07-12
WO2000037459A1 (en) 2000-06-29
PE20001342A1 (es) 2000-12-09
SK7592001A3 (en) 2002-03-05
KR20010081116A (ko) 2001-08-27
NZ511878A (en) 2003-10-31
HUP0202152A2 (en) 2002-10-28
CN1326850C (zh) 2007-07-18
JP2002533336A (ja) 2002-10-08
IL143408A0 (en) 2002-04-21
CO5160350A1 (es) 2002-05-30
BR9916314A (pt) 2001-10-02
NO20012961D0 (no) 2001-06-15
CZ20011950A3 (cs) 2001-12-12
PL348293A1 (en) 2002-05-20
ZA200104233B (en) 2002-08-22

Similar Documents

Publication Publication Date Title
US6372747B1 (en) Farnesyl protein transferase inhibitors
US6239140B1 (en) Compounds useful for inhibition of farnesyl protein transferase
US6124295A (en) Compounds useful for inhibition of farnesyl protein transferase
CA2354774C (en) Farnesyl protein transferase inhibitors
EP0819120A1 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase
CA2354779A1 (en) Tricyclic farnesyl protein transferase inhibitors
EP0989983B1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
EP0927181A1 (en) Tricyclic compounds useful as fpt inhibitors
EP0931079A1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
EP0741722B1 (en) Triazole derivatives
CA2293372C (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
US6689789B2 (en) Compounds useful for inhibition of farnesyl protein transferase
CA2293373C (en) Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase
EP0927179B1 (en) Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors
WO1998057950A1 (en) Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
SK33299A3 (en) Tricyclic compounds useful for inhibition of farnesyl protein transferase

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued